gene in patients relapsing right after treatment Together with the BCL2 antagonist venetoclax. sixty six Resistance to those brokers is associated with these mutations in all over 70% of situations, Though they are usually subclonal as well as their precise role triggering resistance needs to be confirmed.??? "??????????????????????????????????????